FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation

Coverage, in order

1. 5d ago
   FDA Drug Safety / Drugs feed indie

   FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation

   FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.